FINANCINGS
Aeterna Zentaris Inc. priced a public offering for gross proceeds of $16.7 million.
Allena Pharmaceuticals Inc. completed a $53 million series C financing.
Aslan Pharmaceuticals Pte Ltd. raised $34 million in series C funding.
Constellation Pharmaceuticals Inc. completed a $55 million mezzanine round of financing.
Inception IBD closed a $14.1 million series A round.
Kallyope Inc. raised $44 million in series A financing.
Kite Pharma Inc. priced a public offering of about 3.6 million shares at $69 per share for gross proceeds of about $250.1 million.
Rubius Therapeutics Inc. launched with an initial capital commitment of $25 million from Flagship Ventures.
Venture capital firm Sofinnova Partners closed a €300 million (US$328.7 million) fund to support early stage companies.
DEALS
Akeso Biopharma Inc. signed a $200 million out-licensing deal with Merck & Co. Inc.'s MSD China unit.
Applied Genetic Technologies Corp. and Synpromics Ltd. entered a multitarget collaboration for development of new gene therapy candidates.
Bioatla LLC inked a potential $1 billion license and option deal for Pfizer Inc. to use its Conditionally Active Biologics platform for antibody-drug conjugates.
Johnson & Johnson completed its acquisition of Novira Therapeutics Inc.
Pieris Pharmaceuticals Inc. inked an immuno-oncology pact worth up to CHF415 million (US$416 million) with Roche AG.
Pluristem Therapeutics Inc. said United Therapeutics Corp. ended its licensing agreement for the development of PLX-PAD for the treatment of pulmonary arterial hypertension.
PTC Therapeutics Inc. entered a collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA splicing defects.
Rodes Inc. and Ligand Pharmaceuticals Inc. signed exclusive global license and supply agreements for three Captisol-enabled programs.
S1 Biopharma Inc. and Chong Kun Dang Pharmaceutical Corp. entered a commercialization agreement for Lorexys (S1P-104), S1's investigational therapy for hypoactive sexual desire disorder in women.
SQZ Biotech Inc. partnered with Roche AG to develop a cell therapy platform.
Sucampo Pharmaceuticals Inc. said it completed its acquisition of Japanese firm R-Tech Ueno Ltd.
Takeda Pharmaceutical Co. Ltd. and Cour Pharmaceutical Development Co. Inc. partnered to develop immune-modulating therapies for the potential treatment of celiac disease.
. . . AND MORE
See BioWorld Today for coverage of the 2015 American Society of Hematology meeting.
AB Science SA reported a positive readout of its tyrosine kinase inhibitor masitinib in a phase III trial.
Alexion Pharmaceutical Inc. received FDA approval for Kanuma (sebelipase alfa) for lysosomal acid lipase deficiency, or LAL-D.
Armgo Pharma Inc. received FDA orphan drug designation and rare pediatric disease designation for ARM210 for Duchenne muscular dystrophy.
Baxalta Inc. gained U.S. approval of Vonvendi (von Willebrand factor [recombinant]) to treat adults with von Willebrand disease.
Eagle Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd. received FDA approval for Bendeka (bendamustine hydrochloride) injection.
Novo Nordisk A/S is working with IBM Watson Health to create diabetes solutions built on the Watson Health Cloud.
Pfizer Inc. said the FDA accepted for filing and granted priority review for a supplemental new drug application for breast cancer drug Ibrance (palbociclib).
Raptor Pharmaceutical Corp. is moving into registrational studies after reporting 36-month results from a phase II/III trial testing RP103 in Huntington's disease.
South Korea's Ministry of Food and Drug Safety approved domestic sales of Samsung Bioepis Co. Ltd.'s Renflexis (infliximab), a biosimilar of Remicade (infliximab, Johnson & Johnson).
Sanofi Pasteur's dengue vaccine received world-first approval in Mexico.
Spark Therapeutics Inc. earned a $15 million milestone payment from Pfizer Inc. under the firms' collaboration in hemophilia B.
Sunesis Pharmaceuticals Inc. submitted a marketing authorization application with the EMA for vosaroxin to treat acute myeloid leukemia in patients, ages 60 and older.
The FDA's Pulmonary-Allergy Drugs Advisory Committee voiced majority support for the approval of Teva Pharmaceutical Industries Ltd.'s Cinqair (reslizumab) injection for adults with asthma.
Threshold Pharmaceuticals Inc.'s evofosfamide missed its endpoints in phase III trials in pancreatic cancer and soft tissue sarcoma.